Creating a new generation of small molecule protease inhibitors

2017 News Releases

Keyword Search
 
2017 | 2016
DateTitle 
09/14/17KalVista Pharmaceuticals Reports Fiscal First Quarter Results
– Portfolio of Oral Plasma Kallikrein Inhibitors for Treatment of Hereditary Angioedema Continues to Advance – – Intravitreal Diabetic Macular Edema Candidate KVD001 Remains on Track for Phase 2 in 2017 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 14, 2017-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease i... 
Printer Friendly Version
08/08/17KalVista Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, Aug. 08, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017, at 3:05 p.m. EDT in New York City. A live webcast of the presentation may be accessed in the In... 
Printer Friendly Version
07/27/17KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Fourth Quarter and Full Year Financial Results
– Oral Plasma Kallikrein Inhibitor Portfolio for Treatment of Hereditary Angioedema Continues to Advance – – Intravitreal Diabetic Macular Edema Phase 2 On Track to Initiate in 2017 – CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, July 27, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and r... 
Printer Friendly Version
06/01/17KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, June 01, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the Jefferies Healthcare Conference on Thursday, June 8, 2017, at 9:30 a.m. EDT in New York City. A live webcast of the presentation may be accessed in the Investor... 
Printer Friendly Version
05/15/17KalVista Pharmaceuticals to Recognize HAE Day 2017
–  Continuing to Develop a Portfolio of Oral Plasma Kallikrein Inhibitors for Treatment of Hereditary Angioedema and Diabetic Macular Edema – CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, May 15, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today joins the Hereditary Angioedema Association (HAEA) and the entire patient comm... 
Printer Friendly Version
03/16/17KalVista Pharmaceuticals Reports Fiscal Third Quarter Results
–  Continuing to Develop a Portfolio of Oral Plasma Kallikrein Inhibitors for HAE – – Intravitreal DME Program Remains on Track for Phase 2 in 2017 – – Company Expects to be Well-Funded Through Data Inflection Points – CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, March 16, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors,... 
Printer Friendly Version
03/09/17KalVista Pharmaceuticals Appoints Dr. Andreas Maetzel Senior Vice President of Medical
–  Executive Brings Strong Medical and Regulatory Affairs Background and Deep HAE Expertise –CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, March 09, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the appointment of Andreas Maetzel, M.D., M.Sc., Ph.D, to the role of Senior Vice President, Medical."Andreas ... 
Printer Friendly Version